マサチューセッツ州における骨髄異形成症候群の臨床試験
マサチューセッツ州内の拠点で、骨髄異形成症候群に関する21件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06577441Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06484062MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/14更新 · NCT03471260Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
- Massachusetts General Hospital, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06465953The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
被験者募集中第1相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/07/28更新 · NCT07020533A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
12歳以上 · 全性別 · 2026/06/17更新 · NCT04024761Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/17更新 · NCT06138587SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/17更新 · NCT03113643Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- 他2件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/05/07更新 · NCT02269592A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/04/30更新 · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
1歳〜40歳 · 全性別 · 2026/03/12更新 · NCT05292664CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
被験者募集中第2相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/03/10更新 · NCT06059391SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774IS-free Treg HaploHCT
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳〜75歳 · 全性別 · 2025/10/20更新 · NCT04678401HEME Home Transfusion Program
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2025/09/17更新 · NCT06487247Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform
- Shwachman-Diamond Syndrome Alliance Inc., Woburn
被験者募集中観察研究
全年齢 · 全性別 · 2025/05/31更新 · NCT06999954Study of REM-422 in Patients With AML or Higher Risk MDS
- Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2025/04/23更新 · NCT06297941Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2025/04/15更新 · NCT06462365ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。